Objective. To evaluate the prevalence of antineutrophil cytoplasmic antibodies (ANCA) and rheumatic manifestations associated with chronic haematological malignancies.
Haematological malignancies are associated with sysNovember 1998. Seventy-two were female and 128 male. temic, dermatological, rheumatological manifestations
The mean age was 68 yr, ranging from 36 to 96 yr. The and autoantibodies [1] [2] [3] . The mechanisms of these first group (group I ) included 60 patients with de novo manifestations are unknown, but probably linked to MDS, as defined by the French-American-British immune dysfunction induced by the haematological Cooperative Group Classification [4]: refractory anaedisorder, infectious complications or therapy. They usumia (RA), RA with ringed sideroblasts (RARS ), RA ally consist of cutaneous leucocytoclastic vasculitis, with excess blasts (RAEB), RAEB in transformation polyarthritis or neutrophilic dermatitis [1, 2] . In a (RAEB-T ), chronic myelomonocytic leukaemia prospective study, we investigated the prevalence of (CMML (n = 11), classic connective tissue disorders (n = 5). In the literature, systemic vasculitis is rare [12] [13] [14] . Six patients, three in each group, had positive ANCA determination by IIF assay ( Table 1) ; four perinuclear Recently, some authors have emphasized the high frequency of polymyalgia rheumatica associated with MDS pattern with anti-MPO in two, one atypical and one cytoplasmic with no anti-MPO, PR3, elastase, lactofer- [15, 16 ] . Our study was the first to investigate in a prospective rin, lysozyme, or bactericidal/permeability-increasing protein (BPI ) specificity. No patient had ANA or cryoway, the prevalence of rheumatological manifestations during the course of haematological neoplasia. globulinaemia. Among the five patients with perinuclear and atypical ANCA, none had immune manifestations Surprisingly, we found more systemic vasculitis and systemic manifestations than others [6-14], probably and one had neutrophilic dermatitis. The patient with cytoplasmic ANCA fluorescence had CMML associated due to a recruitment bias. In our cohort, rheumatic manifestations (polyarthritis, polymyalgia, vasculitis) with systemic vasculitis. The global prevalence of ANCA positivity in our haematological population was 3%, are more frequent in MDS, particularly in CMML. They occurred in 11 cases out of 60 patients (18%) vs with 5% in group I and 2% in group II. No patient who received IFN-a developed ANCA or rheumatic/vasculseven of 140 (5%) in the lymphoid neoplasia group. In group I, one patient had relapsing polychondritis, which itic manifestations.
Among the 194 ANCA-negative patients, 12 had is often associated with MDS [17] and seven had systemic vasculitis. The vasculitis was systemic, generally vasculitis ( Table 2 ). In the group of MDS, six had medium-size vasculitis fulfilling American College of ANCA negative and involved large-and medium-sized vessels. They fulfilled ACR criteria for classical PAN Rheumatology (ACR) criteria for classic polyarteritis nodosa (PAN ), one had relapsing polychondritis, one and were not associated with hepatitis B or C. No correlation was shown between vasculitis and the activity seronegative polyarthritis, one polymyalgia rheumatica (see Table 2 for others). There was no correlation of the haematological disorder, transfusion frequency, treatments or infectious events. We found no relationbetween rheumatic manifestations, haematological neoplasia, ANCA positivity and cytogenetic findings. In ship between vasculitis, ANCA or cytogenetic abnormalities. Polymyalgia rheumatica and polyarthritis were group II ( Table 2) , five patients had primary vasculitis: relapsing polychondritis, PAN, giant cell arteritis, cutanoted twice in each group and two patients had fasciitis and MDS ( of the lack of specific symptoms, complex haemato-
